TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34604082

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI) - 40 Gy in 10 fractions over 2 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) - 43.5 Gy in 15 fractions over 3 weeks
Number of subjects: 140
Study: 34604088

Group type: EXPERIMENTAL
Intervention: focal prostate SBRT (f-SBRT)
Number of subjects: 18
Study: 34604282

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry supplementation (concentrate or freeze-dried) for 30 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34604285

Group type: EXPERIMENTAL
Intervention: Malnutrition assessment
Number of subjects: 45826

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction category
Number of subjects: 45826
Study: 34604341

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study: 34604546

Group type: EXPERIMENTAL
Intervention: GMCD intervention plus usual care delivered by frontline workers for 12 months, using a digital mobile device interface.
Number of subjects: 624

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 624
Study: 34604752

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg IV Q2W added to first monthly temozolomide cycle
Number of subjects: 30
Study: 34604901

Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg daily
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg daily
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Linezolid dose reduction from 1200 mg to 600 mg based on hemoglobin monitoring
Number of subjects: 109
Study: 34604940

Group type: EXPERIMENTAL
Intervention: aSAH
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: npmSAH
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: pmSAH
Number of subjects: 150
Study: 34605153

Group type: EXPERIMENTAL
Intervention: PrEP programme using smartphone-compatible data collection
Number of subjects: 969
Study: 34605220

Group type: EXPERIMENTAL
Intervention: Mitochondrial respiratory rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coupling efficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myofiber composition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitochondrial reactive oxygen species production
Number of subjects: 0
Study: 34605392

Group type: EXPERIMENTAL
Intervention: Sleeping in a comfortable environment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Limiting naps to 30 minutes
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Maintaining a consistent wake time
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Avoiding alcohol use before bedtime
Number of subjects: 56

Group type: COMPARATOR
Intervention: Actigraphy-measured sleep efficiency
Number of subjects: 56
Study: 34605552

Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim 60 μg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tripegfilgrastim 100 μg/kg
Number of subjects: 27
Study: 34605711

Group type: EXPERIMENTAL
Intervention: School-based intervention program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 34606048

Group type: EXPERIMENTAL
Intervention: Brodalumab
Number of subjects: 929
Study: 34606062

Group type: EXPERIMENTAL
Intervention: Withdrawal of simvastatin without switching to another statin or switching to a hydrophilic statin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Switching to lipophilic atorvastatin
Number of subjects: 34
Study: 34606077

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 1545

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1545
Study: 34606104

Group type: EXPERIMENTAL
Intervention: Skip44
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Skip45
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Skip51
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Skip53
Number of subjects: 142
Study: 34606437

Group type: EXPERIMENTAL
Intervention: Solriamfetol (75-150 mg/day for narcolepsy; 37.5-150 mg/day for OSA)
Number of subjects: 643
Study: 34606501

Group type: EXPERIMENTAL
Intervention: Nifurtimox
Number of subjects: 1497

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 1497
Study: 34606665

Group type: EXPERIMENTAL
Intervention: Tilt-abnormal children (n=10)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls (n=8)
Number of subjects: 10
Study: 34606692

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 168
Study: 34606846

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclooxygenase-2
Number of subjects: 0
Study: 34606847

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colonization of mice with Odoribacter splanchnicus
Number of subjects: 60
Study: 34606881

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) used for lymph node identification and retrieval.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard lymph node harvest techniques (not specified).
Number of subjects: 0
Study: 34607037

Group type: EXPERIMENTAL
Intervention: SBRT followed by pembrolizumab
Number of subjects: 73
Study: 34607210

Group type: EXPERIMENTAL
Intervention: Veliparib 120 mg BID + nivolumab + carboplatin + paclitaxel (C/PAC)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Veliparib 240 mg BID + nivolumab + carboplatin + pemetrexed (C/PEM)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Veliparib (80-240 mg BID) + nivolumab + C/PEM
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study: 34607222

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (200 mg pembrolizumab + 75 mg cisplatin, 4 cycles every 3 weeks)
Number of subjects: 26
Study: 34607341

Group type: EXPERIMENTAL
Intervention: pegylated IFN-α (pegIFNα) administered at 180 μg every 14 days for 4 doses starting at day -1 before HCT
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: pegylated IFN-α (pegIFNα)
Number of subjects: 36
Study: 34607348

Group type: EXPERIMENTAL
Intervention: Cladribine 0.15 mg/kg on days 1 to 5 with 8 weekly rituximab doses of 375 mg/m2 beginning day 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cladribine 0.15 mg/kg with rituximab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cladribine with rituximab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MRD-negative CR at 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lack of MRD in blood at 6 months
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: After progression following CDAR
Number of subjects: 20
Study: 34607377

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Expert Endoscopists
Number of subjects: 500
Study: 34607575

Group type: EXPERIMENTAL
Intervention: SPCQ (single treatment with SP plus chloroquine)
Number of subjects: 1892

Group type: EXPERIMENTAL
Intervention: SPAZ (monthly treatment with sulphadoxine-pyrimethamine plus azithromycin)
Number of subjects: 1892
Study: 34607608

Group type: COMPARATOR
Intervention: Health/Control
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Beekeeping + Health
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Entrepreneurship + Health
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Entrepreneurship + Beekeeping + Health
Number of subjects: 57
Study: 34607609

Group type: EXPERIMENTAL
Intervention: Molecularly matched therapy (≥ 1 therapy)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Personalized combination therapies targeting molecular alterations
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Matching Score (percentage of targeted alterations)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Disease-control rate (stable disease for ≥ 6 months or partial or complete response)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 145
Study: 34607697

Group type: EXPERIMENTAL
Intervention: Topical clascoterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current medications (not specified)
Number of subjects: 0
Study: 34607873

Group type: EXPERIMENTAL
Intervention: Hysterectomy with vaginal vault suspension
Number of subjects: 321

Group type: COMPARATOR
Intervention: Uterine preservation surgical group
Number of subjects: 321
Study: 34607899

Group type: EXPERIMENTAL
Intervention: TIL-based ACT with checkpoint inhibitors (Ipilimumab 3 mg/kg prior to tumor resection and Nivolumab 3 mg/kg every 2 weeks for 4 doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TIL-based ACT with checkpoint inhibitors
Number of subjects: 25
Study: 34608030

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 4
Study: 34608049

Group type: EXPERIMENTAL
Intervention: Caregiver mastery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Known clinical predictors (patient age, Karnofsky Performance Status, type of surgery, O6-methylguanine-DNA-methyltransferase promotor methylation status)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Model with known clinical predictors
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Model with caregiver mastery
Number of subjects: 41
Study: 34608577

Group type: EXPERIMENTAL
Intervention: sEMG amplitude values during stair climbing in children with DMD
Number of subjects: 32

Group type: COMPARATOR
Intervention: sEMG amplitude values during stair climbing in children with DMD (levels II-III)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: sEMG amplitude values and physical performance assessments
Number of subjects: 32
Study: 34608631

Group type: EXPERIMENTAL
Intervention: Efgartigimod 10 mg/kg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Efgartigimod 25 mg/kg
Number of subjects: 34
Study: 34608859

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Responders to MAD treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nonresponders to MAD treatment
Number of subjects: 100
Study: 34609196

Group type: EXPERIMENTAL
Intervention: Deep Learning model for triaging MRI examinations
Number of subjects: 4581
Study: 34609195

Group type: EXPERIMENTAL
Intervention: CT abnormalities at 3-month follow-up
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Repeat imaging at 1-year follow-up
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Persistent breathlessness
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 80
Study: 34609622

Group type: EXPERIMENTAL
Intervention: FA Score based on selected fatty acids (myristic, petroselinic, α-linolenic, arachidonic)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: FA Score
Number of subjects: 462
Study: 34609691

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a single 25-Gy dose
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 8
Study: 34609964

Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with a clone of Plasmodium vivax from Thailand by mosquito-bite CHMI
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Blood-stage CHMI with PvW1 parasite stabilate at 3 different dilutions
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Genomic analysis of PvW1 parasite DNA
Number of subjects: 8
Study: 34610114

Group type: EXPERIMENTAL
Intervention: PWH with COPD
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: PWH without COPD
Number of subjects: 4

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 4
Study: 34610607

Group type: EXPERIMENTAL
Intervention: Methylene blue (1.5 mg kg-1 intravenously)
Number of subjects: 25
Study: 34610756

Group type: EXPERIMENTAL
Intervention: Anlotinib, dosage and duration not specified
Number of subjects: 0
Study: 34610763

Group type: EXPERIMENTAL
Intervention: Severe SVD burden
Number of subjects: 623
Study: 34610808

Group type: EXPERIMENTAL
Intervention: Adherence to WHO handwashing guidelines
Number of subjects: 6064

Group type: EXPERIMENTAL
Intervention: Recent cases of COVID-19 morbidity
Number of subjects: 6064

Group type: EXPERIMENTAL
Intervention: Recent cases of COVID-19 mortality
Number of subjects: 6064
Study: 34610874

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES)
Number of subjects: 6647

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 6647

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients with left main involvement
Number of subjects: 6647

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) in patients with left main involvement
Number of subjects: 6647

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients without left main involvement
Number of subjects: 6647

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) in patients without left main involvement
Number of subjects: 6647
Study: 34610923

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (median 0.9 nmol/L)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Testosterone (median 12.1 nmol/L)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control group (lowest tertile of dihydrotestosterone)
Number of subjects: 243
Study: 34610927

Group type: EXPERIMENTAL
Intervention: General anaesthesia with a standardised anaesthetic protocol for IOP measurement
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anaesthesia for other reasons (Control)
Number of subjects: 100
Study: 34611045

Group type: COMPARATOR
Intervention: Antiplatelet therapy (APT), including aspirin and other antiplatelet drugs, administered to 730 patients (9% of total), with 680 receiving single APT and 50 receiving dual APT.
Number of subjects: 7824
Study: 34611164

Group type: EXPERIMENTAL
Intervention: Afucosylated PfEMP1-specific IgG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subunit PfEMP1 (VAR2CSA) vaccine
Number of subjects: 0
Study: 34611424

Group type: EXPERIMENTAL
Intervention: D-CTAG regimen (decitabine, cytarabine, aclarubicin) with rhTPO and G-CSF
Number of subjects: 0
Study: 34611902

Group type: EXPERIMENTAL
Intervention: Intermittent very low calorie diet (VLCD) with full meal replacement and intensive dietitian support
Number of subjects: 619

Group type: COMPARATOR
Intervention: Interventions aimed at increasing acceptance of weight gain
Number of subjects: 619
Study: 34612019

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3837
Study: 34612058

Group type: EXPERIMENTAL
Intervention: miR-19b-3p
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Baseline level of miR-19b-3p
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Highest quartile of miR-19b-3p level
Number of subjects: 564
Study: 34612495

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation preconception plus during pregnancy
Number of subjects: 1035

Group type: COMPARATOR
Intervention: Multivitamin supplementation during pregnancy only
Number of subjects: 1035
Study: 34613416

Group type: EXPERIMENTAL
Intervention: Telavancin 5 mg/kg IV administered 3 hours before haemodialysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Telavancin 5 mg/kg IV administered post-haemodialysis
Number of subjects: 8
Study: 34613570

Group type: EXPERIMENTAL
Intervention: OBP-801 (1.0 mg/m²)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: OBP-801 (2.0 mg/m²)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: OBP-801 (3.0 mg/m²)
Number of subjects: 3
Study: 34614208

Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0
Study: 34614506

Group type: EXPERIMENTAL
Intervention: Venetoclax (200-400 mg daily starting day -8 for 6-7 doses) plus fludarabine (30 mg/m2 per day for 4 doses) and busulfan (0.8 mg/kg twice daily for 8 doses on day -5 to day -2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard FluBu2 (fludarabine and busulfan)
Number of subjects: 22
Study: 34615429

Group type: EXPERIMENTAL
Intervention: Glycemic load (GL)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Glycemic index (GI)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Adapted dietary inflammatory index (ADII)
Number of subjects: 135
Study: 34615458

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri drops
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo drops without probiotics
Number of subjects: 28
Study: 34615668

Group type: EXPERIMENTAL
Intervention: Patients with COVID-19 (n=52)
Number of subjects: 52
Study: 34615705

Group type: EXPERIMENTAL
Intervention: Human MAIT cells after allogeneic hematopoietic stem cell transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro signals from allogeneic cells and cytokines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vivo model of T-cell-mediated xenogeneic graft-versus-host disease in immunodeficient mice
Number of subjects: 0
Study: 34615718

Group type: EXPERIMENTAL
Intervention: BMS-986148 monotherapy (0.1-1.6 mg/kg i.v. every 3 weeks)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: BMS-986148 once-weekly monotherapy (0.4 or 0.6 mg/kg i.v.)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: BMS-986148 + nivolumab every 3 weeks
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: BMS-986148
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: BMS-986148 + nivolumab
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: BMS-986148 ± nivolumab
Number of subjects: 126
Study: 34615723

Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg) and Ibrutinib (560 mg)
Number of subjects: 37
Study: 34615725

Group type: EXPERIMENTAL
Intervention: Ivuxolimab (0.3 to 10 mg/kg)
Number of subjects: 31
Study: 34615867

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation
Number of subjects: 8
Study: 34616296

Group type: EXPERIMENTAL
Intervention: Bevacizumab as first-line treatment
Number of subjects: 468
Study: 34616588

Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with concurrent chemotherapy (cisplatin 25 mg/m2) and radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent chemotherapy (cisplatin 25 mg/m2) and radiation therapy
Number of subjects: 0
Study: 34616960

Group type: EXPERIMENTAL
Intervention: Colorectal bundle of care implemented gradually during the study period (2018-2021)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colorectal bundle of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of risk factors for SSIs
Number of subjects: 0
Study: 34617591

Group type: EXPERIMENTAL
Intervention: Healthcare intervention strategies to systematically identify familial hypercholesterolaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (incidental approaches)
Number of subjects: 0
Study: 34617912

Group type: EXPERIMENTAL
Intervention: Wearable photoplethysmographic device (Senbiosys)
Number of subjects: 35
Study: 34617915

Group type: EXPERIMENTAL
Intervention: Regular motivational and assessment text messages
Number of subjects: 600

Group type: COMPARATOR
Intervention: Assessment text messages only
Number of subjects: 600
Study: 34618197

Group type: EXPERIMENTAL
Intervention: Single 3-mg dose of PF-06881894
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Single 6-mg dose of PF-06881894
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Multiple 6-mg doses of PF-06881894
Number of subjects: 25

Group type: COMPARATOR
Intervention: PF-06881894 (3- or 6-mg doses)
Number of subjects: 25
Study: 34618321

Group type: EXPERIMENTAL
Intervention: LumiraDx D-Dimer Test (POC)
Number of subjects: 1860
Study: 34618345

Group type: EXPERIMENTAL
Intervention: REC-2282 (AR-42)
Number of subjects: 0
Study: 34618347

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1427
Study: 34618498

Group type: EXPERIMENTAL
Intervention: Digital messaging intervention (0-6 messages daily for 6 months)
Number of subjects: 45
Study: 34618930

Group type: EXPERIMENTAL
Intervention: Diaphragm thickening fraction (TF) >28%
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Diaphragm excursion >25.4 mm
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Left diaphragm thickening fraction (TF) >26.8%
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Left diaphragm excursion >21.5 mm
Number of subjects: 74
Study: 34619098

Group type: EXPERIMENTAL
Intervention: BNT162b2 (tozinameran, Pfizer-BioNTech) vaccine
Number of subjects: 3436957
Study: 34619104

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg (subcutaneous injection) every 4 weeks for three doses, then every 8 weeks thereafter.
Number of subjects: 598
Study: 34619467

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sunitinib (second-line treatment)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Everolimus (second-line treatment)
Number of subjects: 138
Study: 34619678

Group type: EXPERIMENTAL
Intervention: Weight loss (≥10%)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Weight gain (≥10%)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Weight loss (muscle CSAs)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Weight gain (muscle CSAs)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Knee function measures
Number of subjects: 103
Study: 34619987

Group type: EXPERIMENTAL
Intervention: Decreased connectivity of the right basal forebrain to brain stem and basal ganglia
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Increased connectivity of the arousal and attention network regions with the parietal, frontal, and temporal structures in the unaffected hemisphere
Number of subjects: 29
Study: 34620022

Group type: EXPERIMENTAL
Intervention: Acetyl-DL-leucine (ADLL) 3 g/day for 1 week followed by 5 g/day for 3 weeks to 1 year
Number of subjects: 6
Study: 34620071

Group type: EXPERIMENTAL
Intervention: BAPST regimen (Benserazide, Apomorphine, Pantoprazole, Simvastatin, Trimetazidine)
Number of subjects: 0
Study: 34620081

Group type: EXPERIMENTAL
Intervention: Gym Tonic (GT) programme (12 weeks, twice/week)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Wait-list control group (12 weeks)
Number of subjects: 318